Karlan BY - Search Results

1

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.

Wiedemeyer WR, Beach JA, Karlan BY. Wiedemeyer WR, et al. Among authors: karlan by. Front Oncol. 2014 Mar 3;4:34. doi: 10.3389/fonc.2014.00034. eCollection 2014. Front Oncol. 2014. PMID: 24624361 Free PMC article. Review.

2

Genetic factors in ovarian carcinoma.

Li AJ, Karlan BY. Li AJ, et al. Among authors: karlan by. Curr Oncol Rep. 2001 Jan;3(1):27-32. doi: 10.1007/s11912-001-0039-y. Curr Oncol Rep. 2001. PMID: 11123866 Review.

3

ERCC5 is a novel biomarker of ovarian cancer prognosis.

Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler HP, Karlan BY. Walsh CS, et al. Among authors: karlan by. J Clin Oncol. 2008 Jun 20;26(18):2952-8. doi: 10.1200/JCO.2007.13.5806. J Clin Oncol. 2008. PMID: 18565881

4

Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.

Li AJ, McAllister P, Karlan BY. Li AJ, et al. Among authors: karlan by. Gynecol Oncol. 2010 Jan;116(1):105-8. doi: 10.1016/j.ygyno.2009.09.020. Epub 2009 Oct 9. Gynecol Oncol. 2010. PMID: 19818997

5

A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY, Orsulic S. Cheon DJ, et al. Among authors: karlan by. Clin Cancer Res. 2014 Feb 1;20(3):711-23. doi: 10.1158/1078-0432.CCR-13-1256. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218511 Free PMC article.

6

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. Karlan BY, et al. Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22. Gynecol Oncol. 2014. PMID: 24368280

7

A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.

Cass I, Walts AE, Barbuto D, Lester J, Karlan B. Cass I, et al. Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12. Gynecol Oncol. 2014. PMID: 25026639

8

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.

Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR. Taylor-Harding B, et al. Among authors: karlan by. Oncotarget. 2015 Jan 20;6(2):696-714. doi: 10.18632/oncotarget.2673. Oncotarget. 2015. PMID: 25557169 Free PMC article.

9

Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism.

Aspuria PP, Lunt SY, Väremo L, Vergnes L, Gozo M, Beach JA, Salumbides B, Reue K, Wiedemeyer WR, Nielsen J, Karlan BY, Orsulic S. Aspuria PP, et al. Among authors: karlan by. Cancer Metab. 2014 Dec 15;2:21. doi: 10.1186/2049-3002-2-21. eCollection 2014. Cancer Metab. 2014. PMID: 25671108 Free PMC article.

10

ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.

Cheon DJ, Li AJ, Beach JA, Walts AE, Tran H, Lester J, Karlan BY, Orsulic S. Cheon DJ, et al. Among authors: karlan by. Carcinogenesis. 2015 Jul;36(7):739-47. doi: 10.1093/carcin/bgv059. Epub 2015 Apr 29. Carcinogenesis. 2015. PMID: 25926422 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

513 results

Search Page